Zeller C - Search Results

1

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. Packer M, et al. Among authors: zeller c. Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29. Circulation. 2021. PMID: 34459213 Free PMC article. Clinical Trial.

2

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Among authors: zeller c. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Lancet Diabetes Endocrinol. 2014. PMID: 24948511 Clinical Trial.

3

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators. Tikkanen I, et al. Among authors: zeller c. Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30. Diabetes Care. 2015. PMID: 25271206 Clinical Trial.

4

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM trial investigators. Rosenstock J, et al. Among authors: zeller c. Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14. Diabetes Obes Metab. 2015. PMID: 26040302 Free PMC article. Clinical Trial.

5

Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Mancia G, et al. Among authors: zeller c. Hypertension. 2016 Dec;68(6):1355-1364. doi: 10.1161/HYPERTENSIONAHA.116.07703. Epub 2016 Oct 10. Hypertension. 2016. PMID: 27977392 Clinical Trial.

6

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.

Kohler S, Zeller C, Iliev H, Kaspers S. Kohler S, et al. Among authors: zeller c. Adv Ther. 2017 Jul;34(7):1707-1726. doi: 10.1007/s12325-017-0573-0. Epub 2017 Jun 19. Adv Ther. 2017. PMID: 28631216 Free PMC article.

7

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.

Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Kohler S, et al. Among authors: zeller c. Diabetes Care. 2018 Aug;41(8):1809-1816. doi: 10.2337/dc17-1525. Epub 2018 Jun 15. Diabetes Care. 2018. PMID: 29907581

8

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.

Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y. Yabe D, et al. Among authors: zeller c. J Diabetes Investig. 2019 Mar;10(2):418-428. doi: 10.1111/jdi.12910. Epub 2018 Sep 20. J Diabetes Investig. 2019. PMID: 30099847 Free PMC article.

9

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F. Januzzi J, et al. Among authors: zeller c. Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. Eur J Heart Fail. 2019. PMID: 30767353 Free article. No abstract available.

10

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J. Savarese G, et al. Among authors: zeller c. Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. Circulation. 2019. PMID: 30855996 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151 results

Search Page

Filters